belzupacap sarotalocan — Initial data
2026
Development activities for this program are ongoing, with early proof-of-concept data expected in 2026.Source filing
AURA biotech catalysts & pipeline
AURA BIOSCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
belzupacap sarotalocan — Regulatory decision
Q1 2027
Aura expects to provide an update on both programs, including guidance on study completion, in Q1 2027.Source filing
belzupacap sarotalocan — Topline data
Q4 2027
Based on trial activity in recent months and the growing number of potentially eligible patients, the Company currently expects that it can complete CoMpass enrollment in 2026 and provide topline data readout for the 15-month primary endpoint in the fourth quarter of 2027.Source filing